AstraZeneca CEO: Closing In On A Cancer Cure

Biotech is making great strides in oncology.

“I think we are within striking distance of curing some cancers or actually improving survival rates to 90% or above,” AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot told CNBC of the field.